Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-10
DOI
10.1186/s12933-019-0980-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- (2019) Theodosios D. Filippatos et al. POSTGRADUATE MEDICINE
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
- (2019) Damilola D. Adingupu et al. Cardiovascular Diabetology
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
- (2019) Nannan Zhang et al. Cardiovascular Diabetology
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy
- (2019) Toshiyuki Takasu et al. LIFE SCIENCES
- Heart-Failure Therapy — New Drugs but Old Habits?
- (2019) James C. Fang NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’
- (2018) Maayan Waldman et al. Cardiovascular Diabetology
- A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress
- (2018) Yusuf Olgar et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1α axis
- (2018) Maayan Waldman et al. EXPERIMENTAL CELL RESEARCH
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- Caloric restriction ameliorates cardiomyopathy in animal model of diabetes
- (2017) Keren Cohen et al. EXPERIMENTAL CELL RESEARCH
- Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury
- (2017) Pongpan Tanajak et al. JOURNAL OF ENDOCRINOLOGY
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
- (2017) Jennifer M. Trujillo et al. PHARMACOTHERAPY
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications
- (2015) Thomas Münzel et al. EUROPEAN HEART JOURNAL
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intracellular Na+Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+–Glucose Cotransport
- (2015) Rebekah Lambert et al. Journal of the American Heart Association
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
- (2015) Jacob A Udell et al. Lancet Diabetes & Endocrinology
- Arachidonate 12/15-Lipoxygenase–Induced Inflammation and Oxidative Stress Are Involved in the Development of Diabetic Cardiomyopathy
- (2014) Hirofumi Suzuki et al. DIABETES
- Molecular mechanisms of diabetic cardiomyopathy
- (2014) Heiko Bugger et al. DIABETOLOGIA
- Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats
- (2014) N. N. Hamouda et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- 2013 ACCF/AHA Guideline for the Management of Heart Failure
- (2013) Clyde W. Yancy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiac Fibroblast-Dependent Extracellular Matrix Accumulation Is Associated with Diastolic Stiffness in Type 2 Diabetes
- (2013) Kirk R. Hutchinson et al. PLoS One
- Insulin Resistance: Metabolic Mechanisms and Consequences in the Heart
- (2012) E. Dale Abel et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Heart in Diabetes: Not Only a Macrovascular Disease
- (2011) B. Stratmann et al. DIABETES CARE
- Oxidative Stress and Diabetic Complications
- (2010) Ferdinando Giacco et al. CIRCULATION RESEARCH
- Diabetic cardiomyopathy, causes and effects
- (2010) Sihem Boudina et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
- (2009) S. K. Banerjee et al. CARDIOVASCULAR RESEARCH
- Local control of mitochondrial membrane potential, permeability transition pore and reactive oxygen species by calcium and calmodulin in rat ventricular myocytes
- (2009) Keiichi Odagiri et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Calcium-Induced Calcium Release in Skeletal Muscle
- (2009) Makoto Endo PHYSIOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started